Rank-based estimation in the ℓ1-regularized partly linear model for censored outcomes with application to integrated analyses of clinical predictors and gene expression data
From MaRDI portal
Publication:3304984
DOI10.1093/biostatistics/kxp020zbMath1437.62505OpenAlexW2134385763WikidataQ33474260 ScholiaQ33474260MaRDI QIDQ3304984
Publication date: 4 August 2020
Published in: Biostatistics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1093/biostatistics/kxp020
Related Items (8)
A group bridge approach for component selection in nonparametric accelerated failure time additive regression model ⋮ Double penalized semi-parametric signed-rank regression with adaptive LASSO ⋮ Generalized signed-rank estimation and selection for the functional linear model ⋮ Adjusted regularized estimation in the accelerated failure time model with high dimensional covariates ⋮ Robust estimation and selection for single-index regression model ⋮ A semiparametric accelerated failure time partial linear model and its application to breast cancer ⋮ Variable selection in partially linear additive hazards model with grouped covariates and a diverging number of parameters ⋮ Unnamed Item
Uses Software
Cites Work
- Unnamed Item
- Unnamed Item
- Boosting algorithms: regularization, prediction and model fitting
- Estimating regression parameters using linear rank tests for censored data
- Asymptotics for Lasso-type estimators.
- Regularized Estimation in the Accelerated Failure Time Model with High-Dimensional Covariates
- Variable Selection in Semiparametric Linear Regression with Censored Data
- Penalized Estimating Functions and Variable Selection in Semiparametric Regression Models
- Regularized Estimation for the Accelerated Failure Time Model
- Linear rank tests with right censored data
- Rank-based inference for the accelerated failure time model
- A generalized Wilcoxon test for comparing arbitrarily singly-censored samples
This page was built for publication: Rank-based estimation in the ℓ1-regularized partly linear model for censored outcomes with application to integrated analyses of clinical predictors and gene expression data